<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04083430</url>
  </required_header>
  <id_info>
    <org_study_id>YFV_001</org_study_id>
    <nct_id>NCT04083430</nct_id>
  </id_info>
  <brief_title>Cytotoxicity of Yellow Fever Specific CD8 T Cells Following YF-17D Vaccination</brief_title>
  <acronym>CYF-8</acronym>
  <official_title>Cytotoxicity of Yellow Fever Specific CD8 T Cells Following YF-17D Vaccination</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Martin Tolstrup</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigating cytotoxicity of yellow fever specific CD8 T cells following YF-17D vaccination
      and the following licensing of these epitope-specific CD8 T cells
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CD: cluster of differentiation YF: yellow fever
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 8, 2019</start_date>
  <completion_date type="Anticipated">September 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of cytotoxicity of the yellow fever specific (NS4B214LLWNGPMAV222) CD8 T cells 21(+/-3) days after vaccination with YF-17D</measure>
    <time_frame>21(+/-3) days</time_frame>
    <description>Measured by flow cytometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of cytotoxicity of the yellow fever specific (NS4B214LLWNGPMAV222) CD8 T cells 100 (+/- 40) days after vaccination with YF-17D</measure>
    <time_frame>100 (+/- 40) days</time_frame>
    <description>Measured by flow cytometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>% of patients with novel yellow fever vaccine epitopes according to HLA-type defining optimal timepoint for T cell licensing</measure>
    <time_frame>21(+/-3) days</time_frame>
    <description>Measured by polymerase chain reaction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% of patients with novel yellow fever vaccine epitopes according to HLA-type defining optimal timepoint for T cell licensing</measure>
    <time_frame>100 (+/- 40) days</time_frame>
    <description>Measured by polymerase chain reaction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of target cells killed ex vivo from in vivo generated YF-specific CD8+ T cells</measure>
    <time_frame>21(+/-3) days</time_frame>
    <description>Measured by ex vivo killing assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of target cells killed ex vivo from in vivo generated YF-specific CD8+ T cells</measure>
    <time_frame>100 (+/- 40) days</time_frame>
    <description>Measured by ex vivo killing assay</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Healthy</condition>
  <condition>Cytotoxicity</condition>
  <condition>Yellow Fever Vaccination Reaction</condition>
  <arm_group>
    <arm_group_label>Vaccine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Yellow Fever Vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Yellow Fever Vaccine</intervention_name>
    <description>STAMARIL, powder and solvent for suspension for injection in pre-filled syringe.
After reconstitution, 1 dose (0.5 ml) contains: Yellow fever virus1 17D-204 strain (live, attenuated) not less than 1000 IU.
Powder and solvent for suspension for injection.
Before reconstitution, the powder is homogeneous, beige to orange beige, and the solvent is a limpid solution.</description>
    <arm_group_label>Vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18 to 60 years

          -  Informed consent given

        Exclusion Criteria:

          -  Fever (orally &gt;37,5 C) on day of vaccination

          -  Immunosuppressants

          -  Pregnant or breast feeding

          -  Severe immunodeficiency

          -  Known thymus dysfunction

          -  Allergy against egg

          -  Known haemophilia

          -  Previous severe reaction to vaccine

          -  Not willing to use anticonceptives 4 weeks after vaccination
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jesper D Gunst, MD</last_name>
    <phone>+45 40459718</phone>
    <email>jesdam@rm.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesper D Gunst, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>September 2, 2019</study_first_submitted>
  <study_first_submitted_qc>September 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2019</study_first_posted>
  <last_update_submitted>March 24, 2020</last_update_submitted>
  <last_update_submitted_qc>March 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Yellow Fever</mesh_term>
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

